BNP Paribas Exane analyst Navann Ty raised the firm’s price target on Phibro Animal Health (PAHC) to $37 from $24 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Corp’s Earnings Call Highlights Robust Growth
- Phibro Animal Health Faces AI-Driven Risks Threatening Business Stability
- Phibro Animal Health price target raised to $27 from $19 at BofA
- Phibro Animal Health Reports Strong Fiscal Year Results
- Phibro Animal Health: Strong Q4 Results and Strategic Growth Initiatives Tempered by Valuation Concerns Leading to Hold Rating